Shots:
- Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002
- BMS will be responsible for the development & commercialization of DF6002 and its related products, including strategic decisions, regulatory responsibilities, funding, and manufacturing
- DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein, currently being evaluated in P-I/II study for patients with advanced solid tumors, which began in Jul’2020. Additionally, BMS plans to advance the research and development of DF6002 in oncology and hematology
Click here to read full press release/ article | Ref: PRNewswire | Image: Pharmashots
